Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro

Blood

Volumn 102, Issue 9, 2003, Pages 3349-3353

  Ochiai, Naoya ^a   Uchida, Ryo ^b   Fuchida, Shin Ichi ^b   Okano, Akira ^b   Okamoto, Masashi ^b   Ashihara, Eishi ^b   Inaba, Tohru ^b   Fujita, Naohisa ^b   Matsubara, Hiroaki ^b   Shimazaki, Chihiro ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINODACTINOMYCIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOCORTIN 5; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CLONE; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; MYELOMA CELL; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0142078327     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-03-0851     Document Type: Article

References (33)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
2. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789-793.
3. Bjokstrand B, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case matched study from the European Group for blood and marrow transplantation. Blood. 1996;88:4711-4718.
4. Lokhorst A, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031-3037.
5. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001;97:2574-2579.
6. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete rate in multiple myeloma. Blood. 2002;100:755-760.
7. Rowinski EK, Windle JJ, von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
8. Beaupre DM, Kurzrock R. Ras and leukemia: from basic mechanisms to gene-detected therapy. J Clin Oncol. 1999;17:1071-1079.
9. Reuter CWM, Morgan MA, Bergmann L. Targeting the ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood. 2000;96:1655-1669.
10. Corradini P, Ladetto M, Voena C, et al. Mutational activation of N-and K-ras oncogenes in plasma cell dyscrasias. Blood. 1993;81:2708-2713.
11. Paquette RL, Berenson J, Lichtenstein A, McCormic F, Koeffler HP. Oncogenes in multiple myeloma: point mutation of N-ras. Oncogene. 1990; 5:1659-1663.
12. Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trial. Blood. 1996;88:2699-2706.
13. Kalakonda N, Rothwell DG, Scarffe JH, Norton JD. Detection of N-ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma. Blood. 2001;98:1555-1560.
14. Karp JE. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin Hematol. 2001;38(suppl 7):16-23.
15. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effect of the selective farnesyl transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131-137.
16. Gouill SL, Pellat-Deceunynck C, Harroseau J-L, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia. 2002;16:1664-1667.
17. Zujewski J, Horak ID, Bol CJ, et al. Phase 1 and pharmacokinetic study of farnesyl protein transferase inhibitor R 115777 in advanced cancer. J Clin Oncol. 2000;18:927-941.
18. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyl transferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
19. Alshina M, Overton R, Belle N, et al. Farnesyl transferase inhibitor FTI-R115777 is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Proceedings of AACR. 2002;43:1000. Abstract 4960.
20. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor, Zarnestra™ (R115777), in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003;101: 1692-1697.
21. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazder AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991;6:1353-1362.
22. Jego G, Robillard N, Puthier D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood. 1999;94:701-712.
23. 3H]-thymidine incorporation assay. J Immunol Methods. 1994;170:211-224.
24. Herault Q, Colombat P, Domenech J, et al. A rapid single-laser flow cytometric method for discrimination of early apoptotic cells in a heterogenous cell population. Br J Hematol. 1999;104: 530-537.
25. Kohl NE, Wilson FR, Mosser SD, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A. 1994;91:9141-9145.
26. Reichert A, Heisterkamp N, Daley GQ, Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 2001; 97:1399-1403.
27. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404-1412.
28. Mazet JL, Padieu M, Osman H, et al. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-289 disrupts MAP kinase activatiomn and G1-S transition in Ki-Ras-overexpressing transformed adenocortical cells. FEBS Lett. 1999;460:235-240.
29. Sepp-Lorenzino L, Ma Z, Rands E, et al. A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorange-dependent and independent growth of human tumor cell lines. Cancer Res. 1995;15:5302-5309.
30. Bolick SCE, Landowski TH, Boulware D, et al. The farnesyl trasnferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia. 2003;17:451-457.
31. Hu L, Shi Y, Hsu J-H, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic Ras in multiple myeloma cells. Blood. 2003;101: 3126-3135.
32. Rowley M, Liu P, Van Ness B. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicine and melphalan. Blood. 2000;96: 3175-3180.
33. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.